What does this research mean for the field?

Upadacitinib can successfully treat coexisting alopecia areata and hidradenitis suppurativa. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To document the therapeutic response to the selective Janus kinase inhibitor upadacitinib in a patient with concurrent, refractory alopecia areata and hidradenitis suppurativa.

September 2, 2026Anais Brasileiros de DermatologiaOpen Access

Successful treatment of coexisting alopecia areata and hidradenitis suppurativa with upadacitinib

View Full Paper

Ask AI

Bookmark

Authors

PGPatrícia Moreira Gomes RCRúben Costa APAna Pedrosa

Discussion

Member takes

Overview

Case report demonstrates successful management of coexisting alopecia areata and hidradenitis suppurativa with upadacitinib, suggesting shared therapeutic utility of JAK inhibition.

Key Points

To document the therapeutic response to the selective Janus kinase inhibitor upadacitinib in a patient with concurrent, refractory alopecia areata and hidradenitis suppurativa.
Clinical case evaluation of a 24-year-old woman with Down syndrome, hypothyroidism, and concurrent refractory alopecia areata and hidradenitis suppurativa (N=1).
Assessment of disease history following multiple failed treatments, including systemic antibiotics, surgical excision, topical immunotherapies, and corticosteroids.
Upadacitinib therapy achieved successful clinical improvement in both chronic inflammatory skin conditions.
Dual response indicates that selective JAK-STAT pathway inhibition effectively dampens the dysregulated innate and adaptive immune cascades driving both follicular disorders.

Cite This Study

Gomes et al. (2026) studied this question.

synapsesocial.com/papers/6a97e28dc562ede874ec6ba3 https://doi.org/10.1016/j.abd.2026.501453

View Full Paper

Ask AI

Bookmark

September 2, 2026Anais Brasileiros de DermatologiaOpen Access

Successful treatment of coexisting alopecia areata and hidradenitis suppurativa with upadacitinib

View Full Paper

Ask AI

Bookmark

Authors

PGPatrícia Moreira Gomes RCRúben Costa APAna Pedrosa

Discussion

Member takes

Overview

Case report demonstrates successful management of coexisting alopecia areata and hidradenitis suppurativa with upadacitinib, suggesting shared therapeutic utility of JAK inhibition.

Key Points

To document the therapeutic response to the selective Janus kinase inhibitor upadacitinib in a patient with concurrent, refractory alopecia areata and hidradenitis suppurativa.
Clinical case evaluation of a 24-year-old woman with Down syndrome, hypothyroidism, and concurrent refractory alopecia areata and hidradenitis suppurativa (N=1).
Assessment of disease history following multiple failed treatments, including systemic antibiotics, surgical excision, topical immunotherapies, and corticosteroids.
Upadacitinib therapy achieved successful clinical improvement in both chronic inflammatory skin conditions.
Dual response indicates that selective JAK-STAT pathway inhibition effectively dampens the dysregulated innate and adaptive immune cascades driving both follicular disorders.

Cite This Study

Gomes et al. (2026) studied this question.

synapsesocial.com/papers/6a97e28dc562ede874ec6ba3 https://doi.org/10.1016/j.abd.2026.501453

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark